Krystal Biotech (KRYS) EVP, General Counsel discloses initial stock and RSU holdings
Rhea-AI Filing Summary
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles filed an initial ownership report showing his equity interests in the company. This Form 3 does not report any new buy or sell transactions; it lists existing awards and holdings.
He directly holds several stock options, including one with 9,050 shares underlying common stock, and multiple restricted stock unit (RSU) awards, including 3,628 RSUs, along with 642 shares of common stock. Footnotes explain that the options and RSUs generally vest in four equal annual installments beginning around late February in 2024, 2025, and 2026, subject to his continued service, with one option already fully vested.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Thomas John Charles
Role
EVP, General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 61,810 shares (Direct);
Restricted Stock Units — 5,713 shares (Direct);
Common Stock — 642 shares (Direct)
Footnotes (10)
- F1. The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- F2. The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027.
- F3. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
- F4. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
- F5. The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- F6. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date.
- F7. The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- F8. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date.
- F9. The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- F10. The stock option is fully vested.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Form 3 filing by Krystal Biotech (KRYS) executive Thomas John Charles show?
The filing reports Thomas John Charles’s initial ownership in Krystal Biotech, including several stock option grants, multiple restricted stock unit awards, and 642 shares of common stock, without disclosing any new purchase or sale transactions in this report.
What stock option holdings does Thomas John Charles report in Krystal Biotech (KRYS)?
He reports several directly held stock options, including grants with 9,050, 7,500, 2,860, 8,650, 1,350, and 32,400 underlying shares, each subject to vesting terms described in the footnotes tied to grant dates in 2023, 2024, 2025, and 2026.
What restricted stock units (RSUs) does Thomas John Charles hold in Krystal Biotech (KRYS)?
He reports multiple RSU awards, including 3,628, 1,250, and 835 units. Each RSU represents a contingent right to receive one share of common stock, generally vesting in four equal annual installments if he continues serving the company.
How do the vesting schedules work for Thomas John Charles’s Krystal Biotech (KRYS) equity awards?
Most reported stock options and RSUs vest in four equal annual installments starting on grant anniversaries in late February of 2024, 2025, 2026, and 2027, conditioned on his continued service, with one stock option already fully vested according to the footnotes.